FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555390795> ?p ?o ?g. }

• W2555390795 abstract "Background Increasingly, clinicians treating rheumatoid arthritis (RA) or ankylosing spondylitis (AS) are trying to dose-titrate biologics, due to cost, patient preference, and safety. Recent clinical guidelines recommend down titration for RA. However, evidence of safety and efficacy is limited. Objectives Conduct a systematic literature review to assess breadth and quality of published data and evaluate whether sufficient evidence exists to support dose titration of biologics in RA or AS. Methods Medline, Embase, and the Cochrane library were electronically searched on February 2, 2015, and conference abstracts from 2010 to November 2015 were hand searched. Eligible studies included: randomized controlled trials (RCTs), non-RCTs, observational, and pharmacoeconomics. Biologics included: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab. Outcomes were (1) efficacy and sustained remission, (2) flares and retreatment, (3) economic impact. Results The search yielded 21,585 records; after screening, 73 studies in 90 publications/abstracts were retained, including 15 full-text RCTs, 15 full-text non-RCTs and 43 conference abstracts. Efficacy and economic data were limited. Heterogeneity in disease duration, dosing strategies, and definition of treatment success/failure complicated the interpretation and comparison of regimens. Dose titration rationale varied greatly, and few studies used established definitions of flare (table). Level of evidence was low, with most studies presented as conference abstracts. Conclusions Studies evaluating dose titration of biologics are heterogeneous in design and lack standardized definitions. Little evidence of safety and efficacy exists to support dose titration of biologics in RA or AS; RCTs with defined indicators of treatment success and failure are needed. Disclosure of Interest C. S. Lau Consultant for: Abbvie, Astrazeneca, GlaxoSmithKline and Human Genome Sciences, Pfizer, Roche, UCB, A. Gibofsky Shareholder of: AbbVie, Angen, Celgene, Pfizer, GSK, J&J, Regeneron, Consultant for: AbbVie, Celgene, Pfizer, Iroko, Horizon, Samumed, Relburn, Speakers bureau: Amgen, AbbVie, Pfizer, Celgene, Iroko, Horizon, N. Damjanov Consultant for: Pfizer, Roche, MSD, Abbvie, Gedeon-Richter, Boehringer Ingelheim, S. Lula Employee of: Envision Pharma, L. Marshall Shareholder of: Pfizer, Employee of: Pfizer, H. Jones Shareholder of: Pfizer, Employee of: Pfizer, P. Emery Consultant for: Pfizer,MSD,Abbvie,BMS,UCB,Roche,Novartis,Samsung, Sandoz and Lilly" @default.
• W2555390795 created "2016-11-30" @default.
• W2555390795 creator A5002884556 @default.
• W2555390795 creator A5018678002 @default.
• W2555390795 creator A5041835212 @default.
• W2555390795 creator A5059093901 @default.
• W2555390795 creator A5073640857 @default.
• W2555390795 creator A5089566239 @default.
• W2555390795 creator A5090016333 @default.
• W2555390795 date "2016-06-01" @default.
• W2555390795 modified "2023-10-12" @default.
• W2555390795 title "THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review: Table 1." @default.
• W2555390795 doi "https://doi.org/10.1136/annrheumdis-2016-eular.1840" @default.
• W2555390795 hasPublicationYear "2016" @default.
• W2555390795 type Work @default.
• W2555390795 sameAs 2555390795 @default.
• W2555390795 citedByCount "1" @default.
• W2555390795 countsByYear W25553907952021 @default.
• W2555390795 crossrefType "journal-article" @default.
• W2555390795 hasAuthorship W2555390795A5002884556 @default.
• W2555390795 hasAuthorship W2555390795A5018678002 @default.
• W2555390795 hasAuthorship W2555390795A5041835212 @default.
• W2555390795 hasAuthorship W2555390795A5059093901 @default.
• W2555390795 hasAuthorship W2555390795A5073640857 @default.
• W2555390795 hasAuthorship W2555390795A5089566239 @default.
• W2555390795 hasAuthorship W2555390795A5090016333 @default.
• W2555390795 hasConcept C126322002 @default.
• W2555390795 hasConcept C168563851 @default.
• W2555390795 hasConcept C17744445 @default.
• W2555390795 hasConcept C177713679 @default.
• W2555390795 hasConcept C1862650 @default.
• W2555390795 hasConcept C189708586 @default.
• W2555390795 hasConcept C199539241 @default.
• W2555390795 hasConcept C2776215756 @default.
• W2555390795 hasConcept C2776478404 @default.
• W2555390795 hasConcept C2777138892 @default.
• W2555390795 hasConcept C2777178219 @default.
• W2555390795 hasConcept C2777226972 @default.
• W2555390795 hasConcept C2777402515 @default.
• W2555390795 hasConcept C2777575956 @default.
• W2555390795 hasConcept C2778886723 @default.
• W2555390795 hasConcept C2779134260 @default.
• W2555390795 hasConcept C2779338263 @default.
• W2555390795 hasConcept C2779473830 @default.
• W2555390795 hasConcept C2779605438 @default.
• W2555390795 hasConcept C2780132546 @default.
• W2555390795 hasConcept C2780653079 @default.
• W2555390795 hasConcept C2781290027 @default.
• W2555390795 hasConcept C71924100 @default.
• W2555390795 hasConceptScore W2555390795C126322002 @default.
• W2555390795 hasConceptScore W2555390795C168563851 @default.
• W2555390795 hasConceptScore W2555390795C17744445 @default.
• W2555390795 hasConceptScore W2555390795C177713679 @default.
• W2555390795 hasConceptScore W2555390795C1862650 @default.
• W2555390795 hasConceptScore W2555390795C189708586 @default.
• W2555390795 hasConceptScore W2555390795C199539241 @default.
• W2555390795 hasConceptScore W2555390795C2776215756 @default.
• W2555390795 hasConceptScore W2555390795C2776478404 @default.
• W2555390795 hasConceptScore W2555390795C2777138892 @default.
• W2555390795 hasConceptScore W2555390795C2777178219 @default.
• W2555390795 hasConceptScore W2555390795C2777226972 @default.
• W2555390795 hasConceptScore W2555390795C2777402515 @default.
• W2555390795 hasConceptScore W2555390795C2777575956 @default.
• W2555390795 hasConceptScore W2555390795C2778886723 @default.
• W2555390795 hasConceptScore W2555390795C2779134260 @default.
• W2555390795 hasConceptScore W2555390795C2779338263 @default.
• W2555390795 hasConceptScore W2555390795C2779473830 @default.
• W2555390795 hasConceptScore W2555390795C2779605438 @default.
• W2555390795 hasConceptScore W2555390795C2780132546 @default.
• W2555390795 hasConceptScore W2555390795C2780653079 @default.
• W2555390795 hasConceptScore W2555390795C2781290027 @default.
• W2555390795 hasConceptScore W2555390795C71924100 @default.
• W2555390795 hasLocation W25553907951 @default.
• W2555390795 hasOpenAccess W2555390795 @default.
• W2555390795 hasPrimaryLocation W25553907951 @default.
• W2555390795 hasRelatedWork W2321618042 @default.
• W2555390795 hasRelatedWork W2322956565 @default.
• W2555390795 hasRelatedWork W2336559434 @default.
• W2555390795 hasRelatedWork W2414502453 @default.
• W2555390795 hasRelatedWork W2414670302 @default.
• W2555390795 hasRelatedWork W2415016980 @default.
• W2555390795 hasRelatedWork W2486776082 @default.
• W2555390795 hasRelatedWork W2741808992 @default.
• W2555390795 hasRelatedWork W2754101944 @default.
• W2555390795 hasRelatedWork W2755211682 @default.
• W2555390795 hasRelatedWork W2755296718 @default.
• W2555390795 hasRelatedWork W2808502374 @default.
• W2555390795 hasRelatedWork W2808713926 @default.
• W2555390795 hasRelatedWork W2908891110 @default.
• W2555390795 hasRelatedWork W2909935894 @default.
• W2555390795 hasRelatedWork W2950766590 @default.
• W2555390795 hasRelatedWork W2952939036 @default.
• W2555390795 hasRelatedWork W3034982030 @default.
• W2555390795 hasRelatedWork W3082759152 @default.
• W2555390795 hasRelatedWork W3093421183 @default.
• W2555390795 isParatext "false" @default.
• W2555390795 isRetracted "false" @default.
• W2555390795 magId "2555390795" @default.
• W2555390795 workType "article" @default.